Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07204340 · ClinicalTrials.gov registry record · Phase 1
TLN-372 in Advanced KRAS Mutant Solid Tumors
A Phase 1 study of KRAS Mutant Solid Tumors, sponsored by Treeline Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 10
- Study locations
NCT07204340: Recruiting Phase 1 study of KRAS Mutant Solid Tumors, sponsored by Treeline Biosciences.
NCT07204340 is a Phase 1 study of KRAS Mutant Solid Tumors that is actively recruiting participants, run by Treeline Biosciences. The registered enrollment target is 240 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (300% higher). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07204340, a Phase 1 study of KRAS Mutant Solid Tumors, is actively recruiting participants, sponsored by Treeline Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 10
- Study locations
Study Summary
The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors
Conditions Studied
Interventions
- DRUG TLN-372
- DRUG TLN-372 in combination with cetuximab
- DRUG TLN-372 in combination with pembrolizumab
Study Locations (10)
Alabama
- University of Alabama at Birmingham - Birmingham
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- START Midwest - Grand Rapids
Missouri
- Washington University Medical Campus - St Louis
New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Sarah Cannon Research Institute - Nashville
Victoria
- Peter MacCallum Cancer Centre - Melbourne
Western Australia
- Linear Clinical Research - Perth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2032-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07204340
The ClinicalTrials.gov registry entry for NCT07204340 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (300% higher). The listed sponsor is Treeline Biosciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with KRAS Mutant Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which TLN-372 is the first listed.
NCT07204340 reports 10 study locations spanning 10 distinct geographic areas - top geographies include Alabama, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT07204340 about?
NCT07204340 is a clinical study titled "TLN-372 in Advanced KRAS Mutant Solid Tumors". The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors
What is the current status of trial NCT07204340?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2025-09-29. Estimated completion is 2032-04-01.
What conditions does trial NCT07204340 study?
This clinical trial studies the following conditions: KRAS Mutant Solid Tumors.
What interventions are being tested in trial NCT07204340?
The interventions under investigation include: TLN-372 (DRUG), TLN-372 in combination with cetuximab (DRUG), TLN-372 in combination with pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT07204340?
This trial is sponsored by Treeline Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07204340 being conducted?
This trial has 10 study locations across Alabama, Massachusetts, Michigan, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00000665 · 240 participants · NA
Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component
- NCT00000715 · 240 participants · Phase 3
A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia in AIDS
- NCT00032539 · 240 participants
EQUIC-CC: Enhancing Quality of Informed Consent - Customized Consent
- NCT00075907 · 240 participants · Phase 3
Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents
Similar registry start date
- NCT05684068 · started 2028-08 · NA
Dimensional Changes: Randomized Clinical Trial
- NCT07167953 · started 2028-08 · NA
The Spiral MRI Study
- NCT07215013 · started 2028-07 · NA
Acoustic Resonance Therapy for Treating Empty Nose Syndrome
- NCT07443332 · started 2028-07 · NA
Culturally Adapted Contingency Management
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.